Journal
CLINICAL CANCER RESEARCH
Volume 25, Issue 7, Pages 2042-2048Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1078-0432.CCR-18-1625
Keywords
-
Categories
Funding
- Neurosurgery Research & Education Foundation
- B*Cured Research Fellowship Grant
- Society for Immunotherapy of Cancer-AstraZeneca Postdoctoral Cancer Immunotherapy in Combination Therapies Clinical Fellowship Award
- [NIH: R01-NS099463]
- [P50-CA190991]
- [P30-CA14236]
- [R01-CA177476]
- [U01-NS090284]
- [R01-NS085412]
- [R25-NS065743]
Ask authors/readers for more resources
Glioblastoma (GBM) is a devastating disease with an extremely poor prognosis. Immunotherapy via adoptive cell transfer (ACT), especially with T cells engineered to express chimeric antigen receptors (CAR), represents a particularly promising approach. Despite the recent success of CAR T cells for blood cancers, the question remains whether this powerful anticancer therapy will ultimately work for brain tumors, and whether the primary immunologic challenges in this disease, which include antigenic heterogeneity, immune suppression, and T-cell exhaustion, can be adequately addressed. Here, we contextualize these concepts by reviewing recent developments in ACT for GBM, with a special focus on pioneering clinical trials of CAR T-cell therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available